Clinical trial · Interventional
Superb Microvascular Intraocular Tumor Imaging Study (SMITIS)
Using the Superb Microvascular Imaging Method in the Diagnosis of Intraocular Tumors (SMITIS)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The diagnosis and monitoring of intraocular tumors are based on multimodal imaging in addition to the clinical examination (ultra-widefield retinal imaging, echography, angiography). Nevertheless, it may be difficult in cases of retinal hemorrhage, small tumor size or atypical presentation. The study of microvascular flow (Superb Microvascular Imaging, SMI) of intraocular tumors could improve the confidence of differential diagnosis when evaluating these suspicious lesions, or even determine whether a lesion is benign or malignant by describing the vascularization of the lesion. The investigators propose to study the microvascular flow patterns of intraocular tumors prior to proton therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ocular Tumor | Eye Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doppler technology | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intraocular tumor
- description
- New sonographic software technique on ultrasonography to detect low-vascular flow inside intraocular tumors
- interventionNames
- Diagnostic Test: Doppler technology
Primary outcomes (2)
- measure
- Qualitative description of the intratumoral microvascular flow
- timeFrame
- Visite 2 - two weeks after Day 0
- description
- Number of visible feeding pedicles
- measure
- Qualitative description of the intratumoral microvascular flow
- timeFrame
- Month 6
- description
- Number of visible feeding pedicles
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Intraocular tumor not previously treated with proton therapy Exclusion Criteria: * Severe active ocular, periocular or intraocular inflammation * Intraocular pressure \> 30 mmHg
References
Publications (0)
Data not yet available